Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma

Roche, PTC post latest SMA data from their attempt to rival Spinraza, Zolgensma

Source: 
Fierce Biotech
snippet: 

Though a rare condition, the debilitating wasting disease spinal muscular atrophy is gaining a large biopharma interest (and price tags in the millions of dollars), and Roche, with partner PTC Therapeutics, are the latest companies to show their hand in improving kids’ ability to move with the genetic disorder.